Dimension Therapeutics, which is developing novel, liver-directed gene therapies for rare genetic disorders, filed on Monday with the SEC to raise up to $115 million in an initial public offering.
Dimension Therapeutics licenses its AAV vector gene delivery technology from REGENXBIO (RGNX), which is on the IPO calendar to raise $100 million this week.
The Cambridge, MA-based company, which was founded in June 2013, plans to list on the Nasdaq under the symbol DMTX. Dimension Therapeutics initially filed confidentially on July 17, 2015. Goldman Sachs, Citi, Wells Fargo Securities, Canaccord Genuity and Cantor Fitzgerald are the joint bookrunners on the deal. No pricing terms were disclosed.
